FGF7 and COVID-19: Once MSC demonstrates anti-inflammatory, immunomodulatory, anti-fibrotic and antioxidant properties [74,75], the use of its derived EVs may implicate in the improvement of COVID-19 patients’ outcome as they enhance VEGF (Vascular Endothelial Growth Factor), HGF (Hepatocyte Growth Factor), FGF7 (Fibroblast Growth Factor 7), TGF-β signaling pathways, leading to the repair of damaged tissue.